Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University, 7-45-1 Nanakuma Jonan, Fukuoka 814-0180, Japan.
Int J Hematol. 2010 Dec;92(5):762-4. doi: 10.1007/s12185-010-0717-3. Epub 2010 Nov 16.
Combination therapy with interferon-α and zidovudine (IFN/AZT) has been regarded as standard care for acute and indolent (i.e., chronic and smouldering) ATL based on reports involving a limited number of patients. This treatment approach has not been evaluated in Japan, a major endemic area of this disease in the world. This is the first Japanese report of IFN/AZT for ATL. It is impossible to draw any definitive conclusion from this small study; however, IFN/AZT showed clear anti-ATL effects for refractory/relapsed ATL patients. This report would contribute for developing future ATL treatment in Japan.
基于少数患者的报告,干扰素-α和齐多夫定(IFN/AZT)联合治疗已被视为急性和惰性(即慢性和潜伏性)ATL 的标准治疗方法。这种治疗方法尚未在日本进行评估,日本是世界上该疾病的主要流行地区。这是日本首例 IFN/AZT 治疗 ATL 的报告。由于本研究规模较小,因此无法得出任何明确的结论;然而,IFN/AZT 对难治性/复发性 ATL 患者显示出明确的抗 ATL 作用。本报告将有助于日本制定未来的 ATL 治疗方案。